Reset Map7 Results
12358 Parklawn Dr Suite 261 North Bethesda, MD, 20852 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
15601 Crabbs Branch Way, W123 AAVnerGene(Excyte LLC) Rockville, MD, 20855 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
9620 Medical Center Dr, Suite 100 Rockville, MD, 20850 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
401 Professional Dr, Suite 241 Gaithersburg, MD, 20879 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
12358 Parklawn Dr Suite 261 North Bethesda, Maryland, 20852 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
15601 Crabbs Branch Way, W123 AAVnerGene(Excyte LLC) Rockville, Maryland, 20855 United StatesAAVnerGene is a leading biotech company specializing in the development of advanced gene therapy technologies utilizing the AAV platform. Situated in Rockville, Maryland, our state-of-the-art facilities span over 10,000 square feet, housing dedicated spaces for research and development as well as production capabilities. With a leadership team boasting over two decades of experience in the field of AAV gene therapy, along with numerous publications and patents, we are at the forefront of innovation. Our objective is to enhance the accessibility of gene therapy by addressing the bottlenecks in AAV gene therapy. We have introduced groundbreaking AAV production systems known as AAVone and AAVdual. AAVone system employs just a single plasmid for AAV packaging, resulting in a 2-4 fold increase in packaging efficiency. Conversely, the AAVdual system utilizes two plasmids for AAV vector packaging, simultaneously elevating production efficiency while preserving the flexibility to generate various AAV serotypes. We’ve pioneered the ATHENA platform, encompassing ATHENA I, ATHENAII, and ATHENA III, to streamline the process of comparing, selecting, and evolving AAV capsids. ATHENA I is a recognized capsid library designed for the purpose of comparing and selecting the most promising AAV serotypes or variants. ATHENA II, on the other hand, is a random peptide insert library tailored for the development of novel AAV capsids with specific functionalities. Lastly, ATHENA III serves as a rational DNA shuffling library, enabling the creation of innovative hybrid AAV capsids through a deliberate approach. As scientists ourselves, we are fueled by a profound passion to empower fellow researchers in achieving breakthroughs using the AAV platform for gene therapy. We take pride in providing a wide range of AAV products and comprehensive AAV services in AAV design, AAV packaging, AAV analysis, AAV optimization, and AAV capsid library design, construction, production, screening and evolution, to both academic institutions and companies. By collaborating with us, you gain access to our expertise and cutting-edge technologies to propel your research and therapeutic endeavors forward. Together, let us pave the way for a future where gene therapy becomes accessible and transformative for all. Contact us today to explore the vast possibilities of the AAV platform and embark on a journey of scientific discovery and impact. We warmly welcome potential collaborators and investors to join us on this transformative journey. For inquiries and further information, kindly reach out to our esteemed President and CEO, Mr. Daozhan Yu, at daozhan.yu@aavnergene.com. Together, we can drive the future of gene therapy and bring meaningful impact to patients worldwide.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.